Faron Pharmaceuticals Oy (FARN) — Working Capital to Net Assets Ratio
Faron Pharmaceuticals Oy (FARN) has a Working Capital to Net Assets ratio of -43.0% as of June 2025. Working capital of GBX6.98 Million (current assets of GBX14.80 Million minus current liabilities of GBX7.83 Million) is measured against net assets of GBX-16.25 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See FARN equity to assets ratio to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Faron Pharmaceuticals Oy Working Capital to Net Assets (2012–2024)
This chart shows how Faron Pharmaceuticals Oy's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2012 to 2024. As of June 2025, the ratio stands at -43.0%, reflecting working capital of GBX6.98 Million against net assets of GBX-16.25 Million GBX. Check Faron Pharmaceuticals Oy (FARN) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Faron Pharmaceuticals Oy (2012–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Faron Pharmaceuticals Oy from 2012 to 2024, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see FARN company net worth.
| Year | WC/NA Ratio | Working Capital (GBX) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -9.2% | GBX894.00K | GBX-9.76 Million | GBX11.06 Million | GBX10.17 Million | ▼ -49.7 pp |
| 2023 | 40.5% | GBX-6.14 Million | GBX-15.16 Million | GBX8.87 Million | GBX15.01 Million | ▲ +34.1 pp |
| 2022 | 6.5% | GBX-741.00K | GBX-11.48 Million | GBX9.73 Million | GBX10.47 Million | ▼ -159.6 pp |
| 2021 | 166.0% | GBX4.84 Million | GBX2.92 Million | GBX12.02 Million | GBX7.18 Million | ▲ +213.0 pp |
| 2020 | -46.9% | GBX868.00K | GBX-1.85 Million | GBX7.37 Million | GBX6.50 Million | ▼ -241.3 pp |
| 2019 | 194.3% | GBX3.13 Million | GBX1.61 Million | GBX9.20 Million | GBX6.08 Million | ▼ -98.3 pp |
| 2018 | 292.7% | GBX1.08 Million | GBX369.00K | GBX6.83 Million | GBX5.75 Million | ▲ +183.6 pp |
| 2017 | 109.1% | GBX5.17 Million | GBX4.74 Million | GBX13.23 Million | GBX8.06 Million | ▼ -0.8 pp |
| 2016 | 109.9% | GBX11.96 Million | GBX10.88 Million | GBX16.33 Million | GBX4.37 Million | ▲ +6.2 pp |
| 2015 | 103.7% | GBX11.59 Million | GBX11.18 Million | GBX13.79 Million | GBX2.20 Million | ▲ +46.4 pp |
| 2014 | 57.3% | GBX-681.00K | GBX-1.19 Million | GBX981.00K | GBX1.66 Million | ▼ -5.6 pp |
| 2013 | 62.9% | GBX-597.00K | GBX-949.00K | GBX1.14 Million | GBX1.74 Million | ▲ +51.9 pp |
| 2012 | 11.0% | GBX-92.00K | GBX-837.00K | GBX860.00K | GBX952.00K | — |